Radium-223 For mCRPC: The Urologist Perspective - Neal Shore
Radium-223 For Metastatic Castration-resistant Prostate Cancer: The Urologist Perspective - Presented by Neal Shore, MD.
Radium-223 dichloride (radium-223) is an important therapeutic option for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no visceral disease. The unique mechanism of action of this first-in-class alpha-emitting radiopharmaceutical underlies its favorable safety profile and low incidence of myelosuppression. In the pivotal phase 3 ALpharadin in SYMptomatic Prostate CAncer Patients study, radium-223 reduced the risk of death by 30% and prolonged time to first symptomatic skeletal event by 5.8 months. This article summarizes current guidelines and clinical studies that led to the approval of radium-223 as an overall survival therapy, and discusses the urologist’s perspective on using radium-223 in clinical practice. UROLOGY 85: 717e724, 2015. 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
Biography - Neal Shore, MD. FACS
Neal Shore, MD, is an internationally recognized expert in systemic therapies for patients with advanced urologic cancers and innovative therapies to treat patients suffering from prostate enlargement symptoms. Dr. Shore was recently appointed President-Elect of the Large Urology Group Practice Association (LUGPA), which seeks to provide urologists with all the tools they need to effectively care for patients.
Neal D. Shore, MD, FACS, is the Medical Director of the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 100 clinical trials, focusing mainly on prostate and bladder disease.
Dr. Shore is a Certified Physician Investigator who has numerous publications in peer-reviewed journals and has lectured extensively on the treatment of prostate cancer and prostate enlargement. He serves on several industry advisory boards as well as academic and advocacy networks: including the Society Urologic Oncology Clinical Trials Consortium, Bladder Cancer Advocacy Network, Large Urology Group Practice Association, and NCI GU Science Steering Committee. Dr. Shore attended Duke University,’80 and Duke Medical School,’84, Durham, North Carolina. He performed a six-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center/Memorial Sloan-Kettering Cancer Center in New York City in 1990. He is the managing partner for Atlantic Urology Clinics, where he has participated in a full-time clinical practice for the past 18 years.